Supply of reagents and equipment for molecular monitoring of leukaemia

Summary

The Molecular Oncology Laboratory at Asturias Central University Hospital is procuring reagents, consumables and equipment for 24 months to perform molecular monitoring tests for residual leukaemia, covering BCR-ABL p190, BCR-ABL p210 and NPM1 mutations. The quantities are 150, 1,430 and 240 test kits respectively. The planned start date is 1 January 2027, with three possible extensions of up to 12 months each. The tender budget is EUR 242,450 excluding VAT, or EUR 293,364.50 including 21% VAT; the estimated total value, including extensions and a possible modification, is EUR 654,615 excluding VAT. Price is the sole award criterion, and price improvements may be negotiated. In addition to reagents and consumables, the supplier must provide the calibrators and quality-control materials required and make the equipment needed for testing available to the laboratory. The contract includes equipment installation, commissioning and validation, maintenance and repair, staff training, and full integration of the equipment and testing methods with the hospital information systems. Software must be installed at the supplier's expense to transfer results to Gestlab and enable automatic interpretation of positive, negative and indeterminate results. Reagents and equipment must meet the technical specifications and be validated by the laboratory. Equipment must be delivered, installed and validated within 15 calendar days of contract signature. Ordinary orders must be fulfilled within 3 working days and urgent orders within 2 working days. The bid must include technical documentation and the required evidence of suitability. To qualify, the bidder must demonstrate annual turnover of at least EUR 242,450 and a matching value of comparable supplies within the specified period. No bid guarantee is stated, but the successful bidder must provide a final guarantee of EUR 12,122.50.